Axonics Modulation Technologies (AXNX) Receives a Buy from Morgan Stanley

In a report released today, Cecilia Furlong from Morgan Stanley maintained a Buy rating on Axonics Modulation Technologies (AXNXResearch Report), with a price target of $73.00. The company’s shares closed last Friday at $63.52.

According to, Furlong is a 4-star analyst with an average return of 19.6% and a 45.2% success rate. Furlong covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Irhythm Technologies, and Edwards Lifesciences.

Currently, the analyst consensus on Axonics Modulation Technologies is a Strong Buy with an average price target of $73.00, implying a 14.3% upside from current levels. In a report issued on July 12, Nephron also initiated coverage with a Buy rating on the stock with a $75.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $79.81 and a one-year low of $38.41. Currently, Axonics Modulation Technologies has an average volume of 570.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Axonics Modulation Technologies, Inc. operates as a medical technology company, which engages in the design, development, and commercialization of sacral neuromodulation solutions. The firm focuses on the treatment of patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). It offers rechargeable SNM system, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. The company was founded by Guang Qiang Jiang, Danny L. Dearen, Timothy Deer, and Michael V. Williamson in March 2012 and is headquartered in Irvine, CA.

Read More on AXNX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed